CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. , a biotechnology company developing drugs based on its proprietary sugar sequencing technology, will report its financial results for the first quarter ended March 31, 2006 before the U.S. financial markets open on Tuesday, May 9, 2006.
Management will host a conference call on that date at 10:00 am EDT to discuss these results and provide an update on the company. To access the call, please dial 800-510-9691 (domestic) or 617-614-3453 (international) prior to the scheduled conference call time and provide the access code 66598886. A replay of the call will be available approximately two hours after the call and will be accessible through May 16, 2006. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and provide the access code 78876887.
A live audio webcast of the call will be available on the “Investors” section of the Company’s website, http://www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call and will be available through June 9, 2006.
About Momenta:
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic versions of sugar-based and complex drug products. The Company’s most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox(R). Based on its understanding of complex sugars, Momenta has created a diversified pipeline of near-term product opportunities, novel development products and discovery candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at http://www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Michael A. Lawless Momenta Pharmaceuticals, Inc. 617-395-5189
Momenta Pharmaceuticals, Inc.
CONTACT: Michael A. Lawless of Momenta Pharmaceuticals, Inc.,+1-617-395-5189
Web site: http://www.momentapharma.com//
